8-K
filed April 2, 2026, 7:59 PM ET
ticker CLDX
CIK 0000744218
other material
confidence high
sentiment neutral
materiality 0.60
Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch
Celldex Therapeutics, Inc.
- Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.
- Net proceeds expected ~$282M after underwriting discounts and expenses; closing on or about April 6, 2026.
- Underwriters granted 30-day option to purchase up to an additional 1,551,750 shares (15%).
- Proceeds to fund commercial readiness and launch of barzolvolimab for CSU (if approved), clinical/preclinical development, and bispecific platform.
- Lead managers include Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-26-038882
- form_type
- 8-K
- ticker
- CLDX
- cik
- 0000744218
- company_name
- Celldex Therapeutics, Inc.
- filed_at
- 2026-04-02T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:33.698055+00:00
- generated_at
- 2026-05-15T07:54:24.168734+00:00
- sec_items
- ["1.01", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.6
- calibrated_materiality_score
- 0.6
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-26-038882
- json_url
- https://secwatch.observer/filing/0001104659-26-038882.json
- markdown_url
- https://secwatch.observer/filing/0001104659-26-038882.md
- text_url
- https://secwatch.observer/filing/0001104659-26-038882.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/0001104659-26-038882-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/tm267111d2_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
JAGX
Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8
Jaguar Health, Inc.
June 2, 2026, 4:10 PM ET
other_material
Items 1.01, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
On May 26, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 31,958 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”) to Streeterville in exchange for an aggregate of 3.72 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).
Filing page
SEC filing
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).
Filing page
SEC filing
GIPR
Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit
GENERATION INCOME PROPERTIES, INC.
June 1, 2026, 5:27 PM ET
other_material
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent
Filing page
SEC filing
CPSH
CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share
CPS TECHNOLOGIES CORP/DE/
June 1, 2026, 9:35 AM ET
other_material
Items 1.01, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
On May 27, 2026, CPS Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Investors”) for the sale by the Company of 1,200,000 shares (the “Shares”) of its Common Stock, par value $0.01 per share (“Common Stock”), in a registered direct offering (the “Offering”), at a purchase price of $8.00 per share.
Filing page
SEC filing
SAGU
Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE
Shreya Acquisition Group
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference
Filing page
SEC filing
XWIN
XMax raises $3.6M via private placement of 486,500 shares at $7.347/share
XMax Inc.
June 2, 2026, 4:30 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).
Filing page
SEC filing
OSRH
OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP
OSR Holdings, Inc.
June 2, 2026, 1:16 PM ET
other_material
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.
Filing page
SEC filing
VTIX
Virtuix amends warrants to $4.00 exercise price, extends period to July 27, 2026
Virtuix Holdings Inc.
June 2, 2026, 9:15 AM ET
other_material
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).
Comparable filing
On June 1, 2026, Virtuix Holdings Inc. (the “Company”) entered into amendments to each of the following warrants to purchase shares of Class A Common Stock (collectively, the “Warrant Amendments”) with Streeterville Capital, LLC (the “Investor”) amending the exercise price and extending the Reduced Exercise Price Period (as defined below) to each such warrant
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.